Actas dermo-sifiliograficas最新文献

英文中文

Accessibility as a Key Factor in the Clinical Evolution and Therapeutic Management of Patients With Hidradenitis Suppurativa 可及性是化脓性汗腺炎患者临床发展和治疗管理的关键因素。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2026-04-01 Epub Date: 2025-12-31 DOI: 10.1016/j.ad.2025.104589

F.J. León Pérez , C. García Moronta , S.M. Haselgruber de Francisco , D. Muñoz Barba , C. Cuenca Barrales , S. Arias Santiago , A. Molina Leyva

Background and objective

Hidradenitis suppurativa (HS) is a chronic, progressive inflammatory disease with a substantial impact on quality of life. Accessibility to specialized units and referral methods may significantly influence clinical characteristics and therapeutic decisions. This study aims to analyze the relationship between geographical distance, referral method, and the clinical and therapeutic characteristics of patients with HS.

Materials and methods

This was a cross-sectional study including 557 consecutive patients treated between 2017 and 2024 at the HS Unit of Hospital Universitario Virgen de las Nieves. Clinical, demographic, and treatment-related variables were collected. Geographical distance was calculated based on postal codes, and differences between referral methods (teledermatology vs conventional) were analyzed using descriptive and comparative statistical methods.

Results

Patients residing at greater distances presented with more severe disease (Hurley stage III, higher IHS4 scores) and poorer quality of life (DLQI). They also required more intensive treatment regimens, with increased use of biological immunomodulatory drugs. Patients referred via teledermatology were generally younger, had a shorter disease duration, and exhibited milder disease severity at the time of consultation.

Conclusions

Geographical distance and referral method may significantly influence the clinical and therapeutic profiles of patients with HS. These findings underscore the need for strategies to improve accessibility and ensure equitable management. Teledermatology emerges as a valuable tool for early-stage cases, although it should be complemented with in-person assessments for more complex cases.

背景与目的：化脓性汗腺炎（HS）是一种慢性进行性炎症性疾病，严重影响生活质量。专科单位和转诊方法的可及性可能显著影响临床特征和治疗决定。本研究旨在分析地理距离、转诊方式与HS患者临床及治疗特点的关系。材料和方法：这是一项横断面研究，包括557名2017年至2024年在维尔京德拉斯尼夫斯大学医院HS单元连续治疗的患者。收集临床、人口统计学和治疗相关变量。根据邮政编码计算地理距离，并使用描述性和比较统计方法分析转诊方法（远程皮肤科与常规）之间的差异。结果：居住距离越远的患者表现出更严重的疾病（Hurley III期，IHS4评分较高）和更差的生活质量（DLQI）。他们还需要更强化的治疗方案，增加生物免疫调节药物的使用。通过远程皮肤科转诊的患者通常较年轻，病程较短，在会诊时表现出较轻的疾病严重程度。结论：地理距离和转诊方式对HS患者的临床和治疗有显著影响。这些调查结果强调需要制定战略来改善可及性和确保公平管理。远程皮肤病学作为早期病例的一种有价值的工具出现，尽管对于更复杂的病例，它应该与现场评估相辅相成。

{"title":"Accessibility as a Key Factor in the Clinical Evolution and Therapeutic Management of Patients With Hidradenitis Suppurativa","authors":"F.J. León Pérez , C. García Moronta , S.M. Haselgruber de Francisco , D. Muñoz Barba , C. Cuenca Barrales , S. Arias Santiago , A. Molina Leyva","doi":"10.1016/j.ad.2025.104589","DOIUrl":"10.1016/j.ad.2025.104589","url":null,"abstract":"<div><h3>Background and objective</h3><div>Hidradenitis suppurativa (HS) is a chronic, progressive inflammatory disease with a substantial impact on quality of life. Accessibility to specialized units and referral methods may significantly influence clinical characteristics and therapeutic decisions. This study aims to analyze the relationship between geographical distance, referral method, and the clinical and therapeutic characteristics of patients with HS.</div></div><div><h3>Materials and methods</h3><div>This was a cross-sectional study including 557 consecutive patients treated between 2017 and 2024 at the HS Unit of Hospital Universitario Virgen de las Nieves. Clinical, demographic, and treatment-related variables were collected. Geographical distance was calculated based on postal codes, and differences between referral methods (teledermatology vs conventional) were analyzed using descriptive and comparative statistical methods.</div></div><div><h3>Results</h3><div>Patients residing at greater distances presented with more severe disease (Hurley stage III, higher IHS4 scores) and poorer quality of life (DLQI). They also required more intensive treatment regimens, with increased use of biological immunomodulatory drugs. Patients referred via teledermatology were generally younger, had a shorter disease duration, and exhibited milder disease severity at the time of consultation.</div></div><div><h3>Conclusions</h3><div>Geographical distance and referral method may significantly influence the clinical and therapeutic profiles of patients with HS. These findings underscore the need for strategies to improve accessibility and ensure equitable management. Teledermatology emerges as a valuable tool for early-stage cases, although it should be complemented with in-person assessments for more complex cases.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 4","pages":"Article 104589"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145891776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Artificial Intelligence in Cosmetic Dermatology 皮肤病学基础模型：人工智能的进展。叙述性评论。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2026-04-01 Epub Date: 2025-12-17 DOI: 10.1016/j.ad.2025.104560

D.E. Pimienta-Rosero , E.Y. Benavides-Tulcán , D.C. Fajardo-Murcia

Artificial intelligence (AI) has evolved from science fiction into a key tool in everyday life. In cosmetic dermatology, it has revolutionized skin assessment and the development of personalized treatments. Advanced algorithms enable the diagnosis of conditions, predict responses to laser therapies, and optimize dermocosmetic formulations. Mobile applications such as Skiana® and PROVEN Beauty® analyze the skin and recommend products, while clinical devices like VISIA® facilitate diagnosis. Machine learning and deep learning models enhance accuracy in detecting dermatological issues but still face challenges such as data biases and clinical validation. As AI advances, it promises to transform cosmetic dermatology with more efficient and personalized approaches.

基础模型（FMs）是一种深度学习模型，其特点是具有广泛的训练数据和对各种医疗任务的适应性，包括疾病分类、监测、风险分层和治疗计划。它们被分类为大型语言模型（llm）和以视觉为中心的fm，它们分别只处理文本或图像作为输入。另外，一些模型在视觉语言模型（VLMs）中集成了多种模式，如图像和文本，或者可以通过在大型多模式模型（lms）中集成音频、视频、基因组学和患者元数据来扩展这种多模式。FMs有望通过利用先进的人工智能功能，帮助皮肤科医生在临床环境中标准化诊断，更准确地量化疾病严重程度，个性化治疗计划，并最终改善患者的治疗效果。在这篇叙述性综述中，我们概述了生成式人工智能的主要里程碑，这些里程碑推动了以皮肤病学为重点的FMs的发展，这一领域仍在积极研究中。此外，我们总结了目前的景观和主要的医学FMs已经开发了基于图像的医学专业。最后，我们分析了该领域的潜在风险和未来发展方向，并从临床和技术角度提供了见解。

引用次数: 0

Clascoterone 1% in the Treatment of Acne: A Review of its Efficacy, Safety, and Therapeutic Positioning 1% Clascoterone治疗痤疮：疗效、安全性和治疗定位的综述”。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2026-04-01 Epub Date: 2025-12-24 DOI: 10.1016/j.ad.2025.104587

P. Balado-Simó , M. Brufau-Cochs , D. Morgado-Carrasco

Topical clascoterone (TC) is the first topical antiandrogen approved by the Food and Drug Administration (FDA) for the treatment of acne and recently approved in Europe. Through bibliographic searches in Medline and Google Scholar, we conducted a narrative review to assess the usefulness of TC in acne management. Several randomized clinical trials have demonstrated its efficacy and safety (with virtually no systemic adverse effects), but few have compared its effectiveness with other topical agents or its use in combination. It is a highly interesting therapeutic alternative, particularly for patients who do not tolerate other topical treatments or in cases of acne with a strong hormonal component. U.S. treatment guidelines conditionally recommend it for acne management due to its high cost. The strength of recommendation is lower than that of topical retinoids and benzoyl peroxide.

外用clascoterone （TC）是美国食品和药物管理局（FDA）批准的第一个用于治疗痤疮的外用抗雄激素，目前正在欧洲进行批准评估。通过Medline和谷歌Scholar的文献检索，我们进行了一项叙述性回顾，以评估TC在痤疮治疗中的有用性。一些随机临床试验已经证明了其有效性和安全性（几乎没有全身不良反应），但很少将其与其他局部药物或其联合使用的有效性进行比较。这是一个非常有趣的治疗选择，特别是对患者谁不能容忍其他局部治疗或在痤疮与强激素成分的情况下。美国治疗指南有条件地推荐痤疮管理，因为它的高成本。推荐强度低于局部类维生素a和过氧化苯甲酰。

引用次数: 0

Backhaus Towel Clamps: A Noble Ally in the Operating Room Backhaus毛巾夹：手术室的高贵盟友。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2026-04-01 Epub Date: 2025-12-12 DOI: 10.1016/j.ad.2025.104559

A. Bennassar Vicens

引用次数: 0

Survey of Usual Clinical Practice in Patients With Chronic Spontaneous Urticaria Treated With Omalizumab Regarding the Management of Antihistamines 奥玛珠单抗治疗慢性自发性荨麻疹患者抗组胺药管理的临床调查

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2026-04-01 Epub Date: 2025-12-11 DOI: 10.1016/j.ad.2025.104549

E. Gómez de la Fuente , F.J. Ortiz de Frutos , M. Bergón Sendín , G. Melé Ninot

引用次数: 0

A Syndrome With an Unusual Presentation 一种表现不寻常的综合症。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2026-04-01 Epub Date: 2025-12-10 DOI: 10.1016/j.ad.2025.104547

P. Andres-Ibarrola, J. Ugedo Alzaga, M.R. Gonzalez-Hermosa

引用次数: 0

Multiple Pruritic Papules on Bilateral Auricular Concha 双侧耳甲多发瘙痒丘疹。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2026-04-01 Epub Date: 2025-12-10 DOI: 10.1016/j.ad.2025.104552

S. Romero-Romero , M. Iglesias-Sancho , N. Pérez Muñoz

引用次数: 0

RF-New Treatments in Dermatomyositis: Present and Future 皮肌炎的新治疗方法：现在和未来。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2026-04-01 Epub Date: 2025-12-08 DOI: 10.1016/j.ad.2025.104551

M. Mansilla-Polo , P. Balado-Simó , J.M. Mascaró Jr.

引用次数: 0

Oral Roflumilast for Long-term Management of Behçet Spectrum Disorders: A Multicenter Observational Analysis 口服罗氟司特长期治疗行为障碍：一项多中心观察分析。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2026-04-01 Epub Date: 2025-12-12 DOI: 10.1016/j.ad.2025.104561

R. Peñuelas Leal , J.A. Peñuelas Ruiz , Á. González García , L. Bagan , C. Labrandero Hoyos , A. Grau Echevarría , V. Zaragoza Ninet , G. Pérez Pastor , L. García Fernández , M. Linares Barrios , D. Blaya Imbernon , M. Finello , E. Perez Zafrilla , E. Diez Recio , M. Marti Cabrera , J. Bagan , V. Alegre De Miquel

Background

Recurrent aphthous stomatitis (RAS) and Behçet's disease (BD) are part of the Behçet spectrum disorders (BSD), sharing genetic traits and characterized by recurrent ulcers. No systemic treatment is approved for RAS or incomplete BD, despite significant quality-of-life impacts.

Objective

To evaluate the efficacy of roflumilast, a PDE4 inhibitor, in BSD patients and compare responses between RAS and BD.

Methods

This analytical observational study included a total of 33 patients with BSD (22, RAS; 11, BD) from 5 Spanish centers, followed over 52 weeks. Data were collected retrospectively and prospectively, assessing flare-ups, ulcers, pain, and duration. Statistical models compared outcomes across treatment periods.

Results

Roflumilast significantly reduced all studied response variables, with no loss of long-term efficacy. Differences between RAS and BD were minimal and clinically irrelevant. Adverse events occurred in 63% of patients, mostly mild and self-limiting, with tolerability improved through dose adjustments. Two patients (6.25%) dropped out due to adverse events.

Conclusion

Roflumilast is effective for managing BSD, offering a safe option to address unmet needs in RAS and BD. Its favorable safety profile and long-term efficacy support its use in the routine clinical practice.

背景：复发性口疮性口炎（RAS）和behet病（BD）是behet谱系障碍（BSD）的一部分，具有相同的遗传特征，并以复发性溃疡为特征。尽管RAS或不完全性双相障碍对生活质量有显著影响，但尚未批准系统性治疗。目的：评价PDE4抑制剂罗氟米司特治疗BSD患者的疗效，并比较RAS和BSD的疗效。方法：本分析性观察性研究包括来自西班牙5个中心的33例BSD患者（22例RAS， 11例BD），随访52周。回顾性和前瞻性收集数据，评估急性发作、溃疡、疼痛和持续时间。统计模型比较了不同治疗期的结果。结果：罗氟司特显著降低了所有研究的反应变量，没有丧失长期疗效。RAS和BD之间的差异很小，与临床无关。63%的患者发生了不良事件，大多是轻度和自限性的，通过剂量调整可改善耐受性。2例患者（6.25%）因不良事件退出。结论：罗氟司特治疗BSD有效，为解决RAS和BD未满足的需求提供了一种安全的选择，其良好的安全性和长期疗效支持其在常规临床实践中的应用。

{"title":"Oral Roflumilast for Long-term Management of Behçet Spectrum Disorders: A Multicenter Observational Analysis","authors":"R. Peñuelas Leal , J.A. Peñuelas Ruiz , Á. González García , L. Bagan , C. Labrandero Hoyos , A. Grau Echevarría , V. Zaragoza Ninet , G. Pérez Pastor , L. García Fernández , M. Linares Barrios , D. Blaya Imbernon , M. Finello , E. Perez Zafrilla , E. Diez Recio , M. Marti Cabrera , J. Bagan , V. Alegre De Miquel","doi":"10.1016/j.ad.2025.104561","DOIUrl":"10.1016/j.ad.2025.104561","url":null,"abstract":"<div><h3>Background</h3><div>Recurrent aphthous stomatitis (RAS) and Behçet's disease (BD) are part of the Behçet spectrum disorders (BSD), sharing genetic traits and characterized by recurrent ulcers. No systemic treatment is approved for RAS or incomplete BD, despite significant quality-of-life impacts.</div></div><div><h3>Objective</h3><div>To evaluate the efficacy of roflumilast, a PDE4 inhibitor, in BSD patients and compare responses between RAS and BD.</div></div><div><h3>Methods</h3><div>This analytical observational study included a total of 33 patients with BSD (22, RAS; 11, BD) from 5 Spanish centers, followed over 52 weeks. Data were collected retrospectively and prospectively, assessing flare-ups, ulcers, pain, and duration. Statistical models compared outcomes across treatment periods.</div></div><div><h3>Results</h3><div>Roflumilast significantly reduced all studied response variables, with no loss of long-term efficacy. Differences between RAS and BD were minimal and clinically irrelevant. Adverse events occurred in 63% of patients, mostly mild and self-limiting, with tolerability improved through dose adjustments. Two patients (6.25%) dropped out due to adverse events.</div></div><div><h3>Conclusion</h3><div>Roflumilast is effective for managing BSD, offering a safe option to address unmet needs in RAS and BD. Its favorable safety profile and long-term efficacy support its use in the routine clinical practice.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 4","pages":"Article 104561"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Panniculitis Associated With the Diphtheria–Tetanus–Pertussis Vaccine 白喉-破伤风-百日咳三联疫苗引起的全身炎。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2026-04-01 Epub Date: 2025-12-13 DOI: 10.1016/j.ad.2025.104556

Fatima-zahra Agharbi, Ghita Basri, Inas Chikhaoui, Abderrahmane Albouzidi, Mohammed Oukabli, Soumiya Chiheb

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Actas dermo-sifiliograficas

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀